The 7 analysts offering 12-month price forecasts for Aurinia Pharmaceuticals Inc have a median target of 13.00, with a high estimate of 15.00 and a low estimate of 9.50. The median estimate represents a +43.49% increase from the last price of 9.06.
The current consensus among 8 polled investment analysts is to Buy stock in Aurinia Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.14
Reporting Date Mar 14
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.